A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
New England Journal of Medicine2010Vol. 362(5), pp. 416–426
Citations Over TimeTop 1% of 2010 papers
Gavin Giovannoni, Gıancarlo Comı, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch, Steven J. Greenberg
Abstract
Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number, NCT00213135.)
Related Papers
- → Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?(2018)4 cited
- → Health State Utilities In Patients with Relapsing Remitting Multiple Sclerosis Treated with Cladribine Tablets(2017)1 cited
- → In Clarity the Severity and Frequency of Relapses are Lower in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets Versus Placebo(2018)
- Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis(2020)
- → Investigation of Cladribine Treatment Rules in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) by means of Modelling & Simulation(2017)